-
Mashup Score: 0Chemotherapy: Novel Approaches to Prevent and Manage Gastrointestinal Treatment Side Effects - 2 month(s) ago
CancerCare is a national nonprofit organization providing free, professional support services for anyone affected by cancer.
Source: www.cancercare.orgCategories: General Medicine News, NursingTweet
-
Mashup Score: 1The Fundamentals of Chemotherapy | Docwire News - 4 month(s) ago
The Fellow on Call group discusses the fundamentals of chemotherapy, including basic terminology, optimal dosing, and more.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 2
PURPOSE Successful completion of chemotherapy is critical to improve breast cancer outcomes. Relative dose intensity (RDI), defined as the ratio of chemotherapy delivered to prescribed, is a measure of chemotherapy completion and is associated with cancer mortality. The effect of exercise and eating a healthy diet on RDI is unknown. We conducted a randomized trial of an exercise and nutrition intervention on RDI and pathologic complete response (pCR) in women diagnosed with breast cancer initiating chemotherapy. METHODS One hundred seventy-three women with stage I-III breast cancer were randomly assigned to usual care (UC; n = 86) or a home-based exercise and nutrition intervention with counseling sessions delivered by oncology-certified registered dietitians (n = 87). Chemotherapy dose adjustments and delays and pCR were abstracted from electronic medical records. T-tests and chi-square tests were used to examine the effect of the intervention versus UC on RDI and pCR. RESULTS Partici
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
An abstract is unavailable.
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
An abstract is unavailable.
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0A Difficult Pill to Swallow - 6 month(s) ago
Chemotherapy shortages are affecting patients across the country.
Source: www.oncnursingnews.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
The NCCN Best Practices Committeeâs June 2023 survey results found that 93% of cancer centers surveyed at that time were experiencing a shortage of carboplatin, and 70% lacked a steady supply of cisplatin. NCCNâs follow-up survey was conducted from September 6 to 27, 2023. âEveryone with cancer should have access to the best possible treatment according to the latest evidence and expert consensus guidelines,â said Robert W. Carlson, MD, Chief Executive Officer of NCCN. âDrug shortages arenât new, but
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
The survey, completed over 2 weeks in September, follows a similar one released in June.
Source: www.ajmc.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 0Adding The Drug Pembrolizumab to Usual Treatment for People with Advanced Pancreatic Cancer and a BRCA Gene Change | SWOG - 6 month(s) ago
Clinical Trial Summary (S2001) What is the purpose of this clinical trial? This study tests treatment for pancreatic cancer that has spread. It is for people with a BRCA1 or BRCA2 gene change (mutation) that is inherited (passed down in a family). After initial chemotherapy treatment for pancreatic cancer, doctors may…
Source: www.swog.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Olaparib is FDA-approved to treat advanced #pancreatic cancer after initial #chemotherapy for people with BRCA gene mutations. Study S2001 adds pembrolizumab to olaparib for these patients. Learn more at https://t.co/RD8HV4AXah. Or call 1-800-4-CANCER. Ask about S2001. #pancsm https://t.co/OhFtZkTSzM
-
-
Mashup Score: 0Real-World Impact of Prophylactic Growth Factor Use on Timing of Febrile Neutropenia and Infection After High-Risk Chemotherapy - 6 month(s) ago
Background: Prophylactic growth-factor therapy with granulocyte colony-stimulating factor (G-CSF) reduces the risk of febrile neutropenia (FN) in patients with breast cancer initiating myelosuppressive chemotherapy. However, little is known about the protective benefit early in the chemotherapy cycle. Methods: To assess the relationship between G-CSF prophylaxis and incidence of FN/infection in week 1 versus beyond week 1 of the first chemotherapy cycle, a retrospective study was conducted using Medicare claims from 2005 through 2020 among patients with breast cancer initiating high-risk chemotherapy. Two cohorts were compared based on G-CSF prophylaxis within 3 days following chemotherapy initiation. The primary outcome was FN or infection, defined as hospitalization with neutropenia, fever, or infection diagnosis. Secondary outcomes were a stricter definition of FN and infection-related hospitalization. Unadjusted and regression-adjusted proportions of patients experiencing each outc
Source: jnccn.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Join us this month for a free virtual workshop to listen to a team of experts discuss why #chemotherapy causes treatment side effects and discomfort, current research directions to improve control of GI treatment side effects and much more. Register here: https://t.co/Wxp0Dv5Rxw https://t.co/p4UyNXTPPn